| | Diagnosis | Sex/age | Octreotide (dosage, routes of administration) | Effect | Scleroderma | Raynaud’s phenomenon | Diminished esophageal peristalsis | ILD | Diarrhea | Constipation | Antibodies and other features |
| Soudah et al. 1991 | SSc | M/63 | 50 μg, SC | + | + | + | n.a. | + | + | + | Myopathy | SSc | F/65 | 50 μg, SC | + | + | − | n.a. | + | + | − | | SSc | F/60 | 50 μg, SC | + | + | + | n.a. | − | + | + | | SSc | M/57 | 50 μg, SC | + | + | − | n.a. | − | + | + | | SSc | M/55 | 50 μg, SC | + | + | + | n.a. | − | + | + | |
| Kobayashi et al. 1993 | SSc | F/26 | 50 μg, SC | + | + | + | n.a. | n.a. | + | − | |
| Lanting et al. 1993 | SSc/PM | F/51 | 50 μg, SC | + | + | n.a. | + | + | + | − | |
| Yamamoto et al. 1994 | SSc | F/29 | 100 μg, SC | + | + | n.a. | n.a. | + | + | + | α-RNP, myopathy |
| Ono et al. 1996 | SSc | F/28 | 100 μg, SC | + | + | + | n.a. | + | − | + | | SSc | F/47 | 100 μg, SC | + | + | + | n.a. | + | − | − | |
| Kanbe et al. 1996 | SSc | F/61 | 100 μg, SC | + | + | + | n.a. | + | − | + | |
| Ishikawa et al. 1999 | SSc | F/66 | SC | + | + | + | + | + | + | + | | SSc/PM | F/35 | SC | + | + | + | + | − | − | + | α-RNP, Ku |
| Perlemuter et al. 1999 | SS | F/19 | 100 μg, SC | + | − | − | n.a. | n.a. | − | + | α-RNP, SSA | SLE | F/52 | 100–400 μg, SC | + | − | − | n.a. | n.a. | + | + | α-RNP, DNA | SSc | F/70 | 50–100 μg, SC | + | + | + | + | n.a. | − | + | α-Scl-70, Jo-1, PM-1 |
| Descamps et al. 1999 | SSc/PM | F/53 | 75 μg, SC | + | + | + | n.a. | n.a. | − | + | Dysphagia |
| Matsuki et al. 2000 | SSc | M/64 | 50 μg, SC | + | + | + | n.a. | + | − | + | | SSc | F/65 | 100 μg, SC | − | + | + | + | + | − | + | α-Scl-70 |
| Marie et al. 2001 | PM | M/55 | 50 μg, SC | + | − | − | − | − | − | + | |
| Malcolm and Ellard 2001 | SSc | F/75 | 50 μg, SC | − | + | + | − | + | + | − | Intestinal perforation |
| Suzuki et al. 2005 | SSc/PM | F/31 | 100 μg, SC | − | + | + | + | − | − | + | α-Ku |
| Leonardi et al. 2010 | SLE | F/51 | 50 μg, SC | − | − | n.a. | + | n.a. | − | + | PSL pulse was effective |
| Our case 2016 | DM | F/38 | 100 μg IV, 50 μg SC, 30 mg IM | + | − | − | + | + | + | + | α-RNP, SSA, EJ |
|
|